The company said, “The Company expects full-year 2025 net product revenues from JELMYTO to be in the range of $94 to $98 million. This implies a year-over-year growth rate of approximately 8% to 12% over the $87.4 million in demand driven JELMYTO sales in 2024, which excludes the $3.0 million in CREATES Act sales reported in 2024. Full-year 2025 operating expenses are expected to be in the range of $215 to $225 million, including non-cash share-based compensation expense of $11 million to $14 million.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on URGN:
- Options Volatility and Implied Earnings Moves Today, March 10, 2025
- Urogen Pharma (URGN) Q4 Earnings Cheat Sheet
- Urogen Pharma’s Strategic Acquisitions and Pipeline Developments Drive Buy Rating with $64 Price Target
- UroGen Pharma acquires ICVB-1042 from IconOVir Bio for $19M in cash, shares
- UroGen Pharma transferred with Buy rating at Ladenburg
Questions or Comments about the article? Write to editor@tipranks.com